FPE-024

N/A

Report date: 2026/03/19 20:00:18

Base Information

Drug NameFPE-024
Drug Alias NameFPE-024
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulatorsT cell surface glycoprotein CD3 modulators +[4] 
TargetsB-lymphocyte antigen CD19B-cell maturation proteinT cell surface glycoprotein CD3 +[4] 
Therapy Area/IndicationsLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGuangdong Fapon Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesGuangdong Fapon Biopharma Inc
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, Systemic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A